Building 'smart' cell-based therapies

April 17, 2014
Leonard and his team have developed a technology for engineering human cell-based 'devices' that monitor and modify human physiology. This technology is a protein biosensor that sits on the surface of a cell, can be programmed to sense specific external factors, and upon detecting these factors sends a signal into the engineered cell’s nucleus to activate a gene expression program.

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.

Engineering cell-based, biological devices that monitor and modify human physiology is a promising frontier in clinical synthetic biology. However, no existing technology enabled bioengineers to build such devices that sense a patient's physiological state and respond in a customized fashion.

"The project addressed a key gap in the synthetic biology toolbox," says Joshua Leonard, assistant professor of chemical and in Northwestern's McCormick School of Engineering and Applied Science. "There was no way to engineer cells in a manner that allowed them to sense key pieces of information about their environment, which could indicate whether the engineered cell is in healthy tissue or sitting next to a tumor."

Funded by the National Academies Keck Futures Initiative and the Defense Advanced Research Projects Agency, the research is available to read online in the journal ACS Synthetic Biology.

Leonard's team worked for nearly four years to close this gap. The end result is a protein biosensor that sits on the surface of a cell and can be programmed to sense specific external factors. For example, the engineered cell could detect big, soluble protein molecules that indicate that it's next to a tumor. When the biosensor detects such a factor, it sends a signal into the engineered cell's nucleus to activate a gene expression program, such as the production of tumor-killing proteins or chemicals. Since this toxic program would be activated only near tumor cells, such an approach could minimize side effects as well as improve therapeutic benefits.

Called a Modular Extracellular Sensor Architecture (MESA), the biosensor platform is completely self-contained so that several different biosensors can be present in a single cell without interfering with one another, allowing bioengineers to build increasingly sophisticated functional programs. The platform is also highly modular, enabling the biosensors to be customized to recognize factors of relevance to various patients' needs.

"By linking the output of these biosensors to genetic programs, one can build in a certain logical command, such as 'turn the output gene on when you sense this factor but not that factor,'" Leonard explains. "In that way, you could program a cell-based therapy to specify which cells it should kill."

Leonard says doctors could potentially collect immune cells from a patient's body, engineer the cells using MESA, and put them back into the patient. From there, the cells would do the work of detecting cancer or the disease they are designed to identify.

This is the first completely ground-up engineering of a receptor, and now that the core technology has been established, Leonard's team is moving forward to program to recognize specific tumor-associated factors. They are also looking toward applications beyond advanced cell-based therapies.

"This seems to be what always happens in ," he says. "When you start building something, you first learn a lot about the system that you are trying to modify. In the end, you come up with not only useful applications but tools that facilitate basic science."

Explore further: New data for engineering immune cells shows early promise in solid tumors

More information: pubs.acs.org/doi/abs/10.1021/sb400128g

Related Stories

New data for engineering immune cells shows early promise in solid tumors

December 20, 2013
Engineered immune cells, called CARTmeso cells, designed to direct antitumor immune responses toward tumors that carry a protein called mesothelin, showed antitumor activity in two patients with advanced cancers that had ...

Researchers identify transcription factors distinguishing glioblastoma stem cells

April 10, 2014
The activity of four transcription factors – proteins that regulate the expression of other genes – appears to distinguish the small proportion of glioblastoma cells responsible for the aggressiveness and treatment resistance ...

Finding antitumor T cells in a patient's own cancer

November 13, 2013
Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer ...

Recommended for you

New understanding of how muscles work

August 23, 2017
Muscle malfunctions may be as simple as a slight strain after exercise or as serious as heart failure and muscular dystrophy. A new technique developed at McGill now makes it possible to look much more closely at how sarcomeres, ...

Scientists find RNA with special role in nerve healing process

August 22, 2017
Scientists may have identified a new opening to intervene in the process of healing peripheral nerve damage with the discovery that an "anti-sense" RNA (AS-RNA) is expressed when nerves are injured. Their experiments in mice ...

Mouse model of human immune system inadequate for stem cell studies

August 22, 2017
A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School ...

Researchers offer new targets for drugs against fatty liver disease and liver cancer

August 22, 2017
There may no silver bullet for treating liver cancer or fatty liver disease, but knowing the right targets will help scientists develop the most effective treatments. Researchers in Sweden have just identified a number of ...

Link between cells associated with aging and bone loss

August 21, 2017
Mayo Clinic researchers have reported a causal link between senescent cells - the cells associated with aging and age-related disease - and bone loss in mice. Targeting these cells led to an increase in bone mass and strength. ...

Bio-inspired materials give boost to regenerative medicine

August 18, 2017
What if one day, we could teach our bodies to self-heal like a lizard's tail, and make severe injury or disease no more threatening than a paper cut?

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.